Literature DB >> 12922084

Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D.

C Domingo1, I Gadea, M Pardeiro, C Castilla, S Fernández, M A Fernández-Clua, J J De la Cruz Troca, C Punzón, F Soriano, M Fresno, E Tabarés.   

Abstract

A DNA plasmid containing a chimeric sequence encoding both herpes simplex virus type 2 (HSV-2) glycoprotein B (gB) and glycoprotein D (gD) external domains (pcgDB) was used to immunize BALB/c mice against genital HSV-2 infection. To determine the efficacy of this vaccine, groups of mice immunized with the pcgDB plasmid were compared with animals immunized with plasmids corresponding to the individual proteins (pcgBt or pcgDt), administered separately or in combination (pcgBt + pcgDt). We studied the response of the different mouse groups to viral challenge by analyzing clinical disease (vaginitis), serum antibody levels, as well as lymphoproliferative responses and cytokine production by spleen cells. Increased IFN-gamma levels correlated with prolonged survival in mice immunized with the plasmid pcgDB, relative to mice immunized with plasmids coding for the individual proteins alone or in combination. Our results show that immunization with the plasmid encoding the chimeric protein is advantageous over separate proteins. These findings may have important implications for the development of multivalent DNA vaccines against HSV and other complex pathogens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922084     DOI: 10.1016/s0264-410x(03)00423-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs.

Authors:  Mark N Prichard; Ravi Kaiwar; Winthrop T Jackman; Debra C Quenelle; Deborah J Collins; Earl R Kern; George M Kemble; Richard R Spaete
Journal:  Vaccine       Date:  2005-03-19       Impact factor: 3.641

2.  A mucosal vaccination approach for herpes simplex virus type 2.

Authors:  Rebecca S Tirabassi; Christopher I Ace; Tatyana Levchenko; Vladimir P Torchilin; Liisa K Selin; Siwei Nie; Dennis L Guberski; Kejian Yang
Journal:  Vaccine       Date:  2010-12-04       Impact factor: 3.641

3.  A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.

Authors:  Flavia Chiuppesi; Laura Vannucci; Anna De Luca; Michele Lai; Barbara Matteoli; Giulia Freer; Roberto Manservigi; Luca Ceccherini-Nelli; Fabrizio Maggi; Mauro Bendinelli; Mauro Pistello
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

4.  Herpes Simplex Virus 2 Counteracts Neurite Outgrowth Repulsion during Infection in a Nerve Growth Factor-Dependent Manner.

Authors:  Kai A Kropp; Alberto Domingo López-Muñoz; Birgit Ritter; Rocío Martín; Alberto Rastrojo; Sangar Srivaratharajan; Katinka Döhner; Akshay Dhingra; Julia S Czechowicz; Claus-Henning Nagel; Beate Sodeik; Antonio Alcami; Abel Viejo-Borbolla
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

5.  A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice.

Authors:  Julie L Dutton; Bo Li; Wai-Ping Woo; Joshua O Marshak; Yan Xu; Meei-li Huang; Lichun Dong; Ian H Frazer; David M Koelle
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.